Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 217-775-8 | CAS number: 1951-97-9
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Piperazine (CAS No 110-85-0) is the parent molecule from which piperazine, compound with phosphoric acid or piperazine phosphate (CAS No 1951-97-9) is synthesized. In medicine piperazine is used in the form of the hexahydrate or as the citrate, tartrate, phosphate (1951-97-9) or adipate. Thus, piperazine and piperazine phosphate can be considered as belonging to the same category.
Data source
Referenceopen allclose all
- Reference Type:
- publication
- Title:
- Piperazine adipate: a new anthelminthic agent.
- Author:
- Cross BG, David A and Vallance DK
- Year:
- 1 954
- Bibliographic source:
- J. of Pharm. and Pharmacol. 6, 711-717.
- Reference Type:
- publication
- Title:
- Neuromuscular transmission in nematode parasites and antinematodal drug action.
- Author:
- Martin RJ
- Year:
- 1 993
- Bibliographic source:
- Pharmac. Ther. 58, 13-50.
- Reference Type:
- other: study report
- Title:
- European Union Risk Assessment Report : Piperazine
- Author:
- European Chemicals Bureau
- Year:
- 2 005
- Bibliographic source:
- 3rd Priority List Volume: 56;Final Report, 2005
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other:
- Principles of method if other than guideline:
- standard acute method
- GLP compliance:
- not specified
- Test type:
- standard acute method
Test material
- Reference substance name:
- Piperazine
- EC Number:
- 203-808-3
- EC Name:
- Piperazine
- Cas Number:
- 110-85-0
- IUPAC Name:
- piperazine
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- not specified
- Sex:
- not specified
Administration / exposure
- Route of administration:
- oral: unspecified
- Vehicle:
- not specified
- Control animals:
- not specified
Results and discussion
Effect levels
- Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- 2 400 - 4 300 mg/kg bw
- Based on:
- test mat.
Applicant's summary and conclusion
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The acute oral median lethal dose (approx. LD50) of piperazine in mouse was found to be 2400-4300 mg/kg of body weight. Acute toxicity of piperazine to mouse indicates that piperazine does not exhibits acute toxicity by the oral route within above mention dose.
- Executive summary:
The acute oral median lethal dose (approx. LD50) of piperazine in mouse was found to be 2400-4300 mg/kg of body weight. Acute toxicity of piperazine to mouse indicates that piperazine does not exhibits acute toxicity by the oral route within above mention dose.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
